CD274 and pancreatic neoplasm: Finally, preliminary trials of checkpoint inhibitors in pancreatic cancer have yielded disappointing results for ipilimumab (anti-CTLA-4) [46] and anti-PD-L1 antibodies [25,47], and PDAC is known as the “dark side” of immunotherapy [48].